All lobbying filings

AVENUE SOLUTIONS

Lobbying for VERTEX PHARMACEUTICALS INCORPORATED · Biopharmaceutical company

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · Massachusetts · House · Senate · $60,000.00 income · posted Jul 21, 2025

Official filing document

Bills named in this filing 8

HR 1227
Alternatives to PAIN Act
S 475
Alternatives to PAIN Act
HR 1672
Maintaining Investments in New Innovation Act
HR 2484
Seniors’ Access to Critical Medications Act of 2025
HR 946
ORPHAN Cures Act
S 1862
ORPHAN Cures Act
HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
HCONRES 14
Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appro…

Lobbying activity 2

Medicare/Medicaid

H.R. 1227/S. 475, Alternatives to PAIN Act and issues related to payment policies for non-opioid pain medication; H.R. 1672, Maintaining Investments in New Innovation Act; Biosimilars Access and Affordability Act; H.R. 2484, Seniors Access to Critical Medications Act; H.R. 946/S. 1862, ORPHAN Cures Act; Issues related to PBM reform; Issues related to Most Favored Nation (MFN) drug pricing proposal

Health Issues

Monitor issues related to 340b; Health care issues in H.R. 1, To provide for reconciliation pursuant to title II of H. Con. Res. 14 (Public Law No: 119-21)

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.